The Wockhardt Group, once a prominent player in the pharmaceutical industry, is facing severe difficulties. With mounting debts and a struggling business, the group's valuable assets are now headed to market. This dramatic turn of events has sent shockwaves through the industry, leaving many observers. It remains to be seen who will ultimately acq